Complete Remission Reported in Patient in Ongoing Trial of APVO436
News
Aptevo Therapeutics’ investigational therapy APVO436 resulted in a patient’s complete disease remission in an ongoing trial in people with relapsed or refractory acute myeloid leukemia (AML) and high-grade myelodysplastic syndrome (MDS), the company announced. ... Read more